Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis

Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $453.51 to $464.23
• 50-Day Range: $436.00 to $479.53
• 52-Week Range: $377.85 to $519.88
• Volume: 1.86 million shs
• Average Volume: 1.04 million shs
• Market Capitalization: $118.67 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $509.89
• Consensus Rating: Moderate Buy

Vertex Pharmaceuticals Stock Analysis - MarketRank™

Vertex Pharmaceuticals scored higher than 87% of companies evaluated by MarketBeat, and ranked 129th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 11 buy ratings, 14 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Vertex Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 12.03%

Earnings Growth

Earnings for Vertex Pharmaceuticals are expected to grow by 12.03% in the coming year, from $15.63 to $17.51 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vertex Pharmaceuticals is -117.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vertex Pharmaceuticals is -117.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vertex Pharmaceuticals has a P/B Ratio of 7.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.64% of the float of Vertex Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vertex Pharmaceuticals has recently increased by 4,237.47%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vertex Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Vertex Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.3 / 5
• Environmental Score: -3.12

Percentage of Shares Shorted

1.64% of the float of Vertex Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vertex Pharmaceuticals has recently increased by 4,237.47%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.38

News Sentiment

Vertex Pharmaceuticals has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 36 news articles for Vertex Pharmaceuticals this week, compared to 31 articles on an average week.

Search Interest

30 people have searched for VRTX on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.

MarketBeat Follows

Only 11 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -31% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,084.00 in company stock.

Percentage Held by Insiders

Only 0.20% of the stock of Vertex Pharmaceuticals is held by insiders.

Percentage Held by Institutions

90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VRTX Stock Analysis - Frequently Asked Questions

How have VRTX shares performed this year?

Vertex Pharmaceuticals' stock was trading at $402.70 on January 1st, 2025. Since then, VRTX shares have increased by 14.8% and is now trading at $462.13.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its quarterly earnings data on Monday, May, 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by $0.23. The firm's quarterly revenue was up 2.6% on a year-over-year basis.
Read the conference call transcript.

Does Vertex Pharmaceuticals have any subsidiaries?

Vertex Pharmaceuticals subsidiaries include V2X, Semma Therapeutics, Exonics Therapeutics, Aurora Biosciences Corporation, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, and others.

Who are Vertex Pharmaceuticals' major shareholders?

Top institutional investors of Vertex Pharmaceuticals include Jennison Associates LLC (2.40%), WCM Investment Management LLC (0.45%), Sumitomo Mitsui Trust Group Inc. (0.26%) and DekaBank Deutsche Girozentrale (0.20%). Insiders that own company stock include Reshma Kewalramani, Stuart A Arbuckle, Amit Sachdev, Ourania Tatsis, Charles F Wagner Jr, Bruce I Sachs, Bastiano Sanna, David Altshuler, Carmen Bozic, Edward Morrow Atkinson III, Jonathan Biller, Jeffrey M Leiden, Kristen Ambrose, Joy Liu, Sangeeta N Bhatia and Yuchun Lee.
View institutional ownership trends.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vertex Pharmaceuticals investors own include Salesforce (CRM), Chevron (CVX), QUALCOMM (QCOM), AbbVie (ABBV), Home Depot (HD), CocaCola (KO) and Bristol Myers Squibb (BMY).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 8/02/2025
• Next Earnings (Confirmed): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VRTX
• CIK: 875320
• Web: www.vrtx.com
• Phone: (617) 341-6100
• Fax: 617-576-2109
• Employees: 6,100
• Year Founded: 1989

Price Target and Rating

• Average Price Target for Vertex Pharmaceuticals: $509.89
• High Price Target: $586.00
• Low Price Target: $420.00
• Potential Upside/Downside: +10.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 26 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 29.57
• P/E Growth: N/A
• Net Income: -$535.60 million
• Net Margins: -8.91%
• Pretax Margin: -2.70%
• Return on Equity: -3.36%
• Return on Assets: -2.42%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 2.65
• Quick Ratio: 2.29

Sales & Book Value

• Annual Sales: $11.02 billion
• Price / Sales: 10.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $63.72 per share
• Price / Book: 7.25

Miscellaneous

• Outstanding Shares: 256,800,000
• Free Float: 256,283,000
• Market Cap: $118.67 billion
• Optionable: Optionable
• Beta: 0.44